SCHEMBL19813655

SCHEMBL19813655

C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)C[C@@H]1O)Oc1ccccc1)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.58
ENPP1 P22413 3/20 0.57
P2RY1 P47900 2/20 0.57
DTYMK P23919 4/20 0.48
TRPM2 O94759 2/20 0.47
DNPH1 O43598 1/20 0.47
PRKAB2 O43741 1/20 0.47
LDHA P00338 1/20 0.47
ADRB2 P07550 1/20 0.47
FBP1 P09467 1/20 0.47
SRC P12931 1/20 0.47
ADORA1 P30542 1/20 0.47
P2RY2 P41231 1/20 0.47
PRKAG1 P54619 1/20 0.47
PRKAA2 P54646 1/20 0.47
PDE4D Q08499 1/20 0.47
KCNH2 Q12809 1/20 0.47
PRKAA1 Q13131 1/20 0.47
PDE3A Q14432 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19813708 1.00 POLB (0.58) POLBENPP1P2RY1DTYMKTRPM2
SCHEMBL22348860 0.94 POLB (0.56) POLBENPP1P2RY1DTYMKTRPM2
SCHEMBL23187796 0.94 POLB (0.56) POLBENPP1P2RY1DTYMKTRPM2
SCHEMBL22348823 0.93 POLB (0.55) POLBENPP1P2RY1DTYMKNT5E
SCHEMBL21162567 0.93 POLB (0.55) POLBENPP1P2RY1DTYMKNT5E
SCHEMBL23187793 0.93 POLB (0.55) POLBENPP1P2RY1DTYMKNT5E
SCHEMBL21162566 0.92 POLB (0.54) POLBENPP1P2RY1DTYMKP2RY2
SCHEMBL19821262 0.92 POLB (0.54) POLBENPP1P2RY1DTYMKTRPM2
SCHEMBL22348794 0.92 POLB (0.54) POLBENPP1P2RY1DTYMKP2RY2
SCHEMBL22348799 0.92 POLB (0.54) POLBENPP1P2RY1DTYMKP2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3331354-A1 PHOSPHORAMIDATE NUCLEOSIDE PRODRUG FOR TREATING VIRAL DISEASES AND CANCER, PROCESSES FOR THEIR PREPARATION AND THEIR USE Asavi, LLC (US) 2018-06-13 EP claimed
WO-2018022221-A1 PHOSPHORAMIDATE NUCLEOSIDE PRODRUG FOR TREATING VIRAL DISEASES AND CANCER, PROCESSES FOR THEIR PREPARATION AND THEIR USE ASAVI, LLC (US) 2018-02-01 WO claimed
US-20180030080-A1 Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use IVACHTCHENKO ALEXANDRE VASILIEVICH (US) 2018-02-01 US claimed
EP-3331354-A1 PHOSPHORAMIDATE NUCLEOSIDE PRODRUG FOR TREATING VIRAL DISEASES AND CANCER, PROCESSES FOR THEIR PREPARATION AND THEIR USE Asavi, LLC (US) 2018-06-13 EP disclosed
WO-2018022221-A1 PHOSPHORAMIDATE NUCLEOSIDE PRODRUG FOR TREATING VIRAL DISEASES AND CANCER, PROCESSES FOR THEIR PREPARATION AND THEIR USE ASAVI, LLC (US) 2018-02-01 WO disclosed
US-20180030080-A1 Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use IVACHTCHENKO ALEXANDRE VASILIEVICH (US) 2018-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180030080-A1 Phosphoramidate nucleoside prodrug for treating viral diseases and cancer, processes for their preparation and their use HCCS, NTPCR, NSUN2 POLB 55/4885ENPP1 695/4885P2RY1 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.